FAME Substudy: FFR-Guided PCI Benefits Women, Men Equally
Click Here to Manage Email Alerts
Angiographic lesions of similar severity were less likely to produce ischemia in women than men, and a fractional flow reserve-guided PCI strategy benefited both sexes equally, substudy results of the FAME trial found.
In all, researchers analyzed data of 744 men and 261 women from the FAME trial who had multivessel coronary disease and were randomly assigned to angiography- or FFR-guided PCI to evaluate the effect of gender on treatment methods.
Men and women had similar rates of MACE (20.2% vs. 20.3%; P=.923), death (3.4% vs. 2.7%; P=.591), MI (8.1% vs. 7.7%; P=.837), repeat revascularization (11.4% vs. 12.3%; P=.717) and 2-year MACE-free survival (78.8 ± 1.5% vs. 78.6 ± 2.6%; P=.82).
Women had significantly higher FFR values than men (0.75 ± 0.18 vs. 0.71 ± 0.17; P=.001). Functionally significant lesions (FFR ≤0.8) were lower in women for lesions with 50% to 70% stenosis (21.1% vs. 39.5%; P<.001) and for lesions with 70% to 90% stenosis (71.9% vs. 82%; P=.019). Patients with functionally significant lesions of 91% to 99% did not differ between the sexes (97.5% vs. 96.2%; P=.682).
Researchers wrote that women had a lower proportion of functionally significant lesions than men with coronary stenoses between 50% and 90% narrowed; that an FFR-guided PCI strategy benefited men and women equally; and 2-year rates of cardiac events were similar between the sexes regardless of treatment strategy, although women were older and tended to have higher rates of baseline comorbidities.